This article is more than 5 years old. Information may no longer be current.
PROs from patients with RA similar between Orencia, Humira at 2 years
Click Here to Manage Email Alerts
Patient-reported outcomes were similar between patients with rheumatoid arthritis treated with Orencia or Humira in addition to background therapy with methotrexate, and the reported outcomes correlated with outcomes reported by physicians, according to a recently published study.
Researchers studied 646 patients with rheumatoid arthritis (RA) randomized to Orencia (abatacept, Bristol-Meyers Squibb) or Humira (adalimumab, AbbVie) in the AMPLE study. Of 318 patients randomized to abatacept and 328 patients randomized to adalimumab, 79.2% and 74.7% completed 2 years of study, respectively. Patient characteristics were similar in both groups.
The patient-reported outcomes (PROs) included pain, fatigue and the ability to perform work and daily activities.
The mean improvement in pain at year 2 was 53.7% in patients who received abatacept compared to 38.5% at 2 years and a minimal clinically important difference (MCID) was reached by day 15 in both treatment groups. At 2 years, comparable improvements in fatigue were observed and the MCID of a decrease of 10 mm on VAS was met by day 15 in both groups.
The ability to perform work was comparable between the treatment groups and an MCID of 7% in the components of reduced impairment while working, overall reduced work impairment and gains in activity were met in both groups at month 6, year 1 and year 2. Patients in both groups reported comparable increases in the ability to perform daily activities, and the MCID of 4 additional days of ability to perform daily activities was reached at month 6, year 1 and year 2.
In all clinical outcomes assessed, patients who responded to treatment were more likely to have higher PROs than patients who did not respond. Lower disease activity was associated with improved PRO scores. – by Shirley Pulawski
Disclosure: Fleischmann reports the receipt of research grants of more than $10,000, from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and UCB, and consultancy fees of less than $10,000 from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Roche, Sanofi-Aventis, and UCB. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts